At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
SAGE-217 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 in the Treatment of Subjects With Essential Tremor
In Brief
A Phase 2 clinical trial evaluating SAGE-217 and Placebo for Essential Tremor. Completed, enrolled 34 participants across 26 sites.
Detailed Summary
This study is a three-part, multicenter, Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of SAGE-217 in adult participants with essential tremor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Tremor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartMar 2017
Primary CompletionNov 2017
Study CompletionDec 2017
TodayJul 2026
First PostedDec 1, 2016
Enrollment StartMar 24, 2017
Primary CompletionNov 22, 2017
Study CompletionDec 5, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.6 years ago
Interventions
SAGE-217drug
SAGE-217 Oral Solution
SAGE-217drug
SAGE-217 Capsules
Placebodrug
SAGE-217 matching placebo capsules